Kezar Life Sciences, Inc.KZRNASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank33
Studio
Year-over-Year Change

Operating cash flow minus capital expenditures

Latest
$-56.66M
↓ 33% vs avg
Percentile
P33
Within normal range
Streak
2 yr
Consecutive growthContracting
Average
$-42.55M
Historical baseline
PeriodValueYoY Change
TTM$-56.66M+23.7%
2024$-74.24M+11.0%
2023$-83.45M-38.1%
2022$-60.42M-41.3%
2021$-42.75M-15.1%
2020$-37.14M-21.8%
2019$-30.48M-39.1%
2018$-21.91M-157.8%
2017$-8.50M+14.1%
2016$-9.89M-